United Kingdom Pharmaceutical Cdmo Market Insight
Published: 25 May 2026 | Report Format: Electronic (PDF)
The UK pharmaceutical Cdmo market size is rapidly expanding, at about a 7.74% CAGR, and the biologics demand, R&D expansion, and advanced drug manufacturing services
UK Pharmaceutical Cdmo Market Insights Forecasts to 2035
- The UK Pharmaceutical Cdmo Market Size Was Estimated at USD 6.901 Million in 2025
- The Market Size is Expected to Grow at a CAGR of around 7.74% from 2025 to 2035
- The UK Pharmaceutical Cdmo Market Size is Expected to Reach USD 14.542 Million by 2035
Notable Insights for UK Pharmaceutical Cdmo Market
- Biologics manufacturing services have captured about 37% share of the UK pharmaceutical CDMO market, mainly because of monoclonal antibodies, biosimilar and precision medicines, thanks to £8-12 billion worth of global biologics manufacturing capacity investment.
- The formulations and drug development accounted for almost 29% of the total UK CDMO market size because of the rise in outsourcing of clinical formulations and oral solid dosage drugs, along with investments made globally worth £5-7 billion in drug development and formulations.
- In the investment worth USD 3.5 billion, the UK government on life sciences innovations and manufacturing of biopharmaceuticals, and R&D of biopharmaceuticals and other health research and developments.
- The expansion in the market for Advanced Therapy Medicinal Products (ATMPs), including cell and gene therapy products, is fuelling investment in CDMO facilities, estimated to be worth USD 10-15 billion worldwide, with compliant manufacture accounting for about 15-20% of outsourcing.
Download the eBook (ToC)
Why Buy This Report
- Detailed United Kingdom Pharmaceutical CDMO Market covering topics like biologics manufacturing, advanced therapies, AI-based drug discovery, and the transformation of healthcare manufacturing.
- See how precision medicine, cell & gene therapy manufacturing, continuous manufacturing processes, and outsourced drug discovery R&D are impacting the UK CDMO landscape.
- Discover new investment prospects arising from the growing biologics manufacturing capacity, vaccine manufacturing facilities, advanced therapies manufacturing, and pharmaceutical logistics solutions in the UK.
- Analyze the emerging regulatory environment, the modernization of life sciences, and biopharma innovation trends that will impact CDMO adoption in the UK.
Competitive Analysis:
The report offers the appropriate analysis of the key organizations/companies involved within the UK pharmaceutical Cdmo market, along with a comparative evaluation primarily based on their product of offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.
Top Companies in United Kingdom Pharmaceutical Cdmo Market
- Lonza Group AG
- Catalent Inc.
- Recipharm AB
- Thermo Fisher Scientific Inc.
- WuXi AppTec
- Samsung Biologics
- Almac Group
- PCI Pharma Services
- Others
Recent Developments:
- In February 2026, Lonza Group AG, Switzerland, expanded biologics and cell therapy CDMO capacity across Europe. Backed by USD 1–2 billion CAPEX, it strengthened GMP manufacturing, precision medicine supply, and UK-linked biopharma outsourcing growth.
- In October 2025, Catalent Inc., United States, expanded sterile injectables and biologics CDMO capabilities, advancing clinical manufacturing and drug delivery systems. Supported by USD 500M–1Billion investments, strengthening global outsourcing and UK-linked pharmaceutical supply chains.
Market Segmentation:
United Kingdom Pharmaceutical CDMO Market, By Service Type
- Drug Development Services
- Manufacturing Services
- Packaging Services
- Analytical Testing Services
- Others
United Kingdom Pharmaceutical CDMO Market, By Product Type
- Small Molecules
- Biologics
- Cell & Gene Therapies
- Vaccines
- Others
United Kingdom Pharmaceutical CDMO Market, By Application
- Oncology
- Infectious Diseases
- Neurology
- Cardiovascular Diseases
- Rare Diseases
- Others
United Kingdom Pharmaceutical CDMO Market, By End User
- Pharmaceutical Companies
- Biotechnology Companies
- Research Institutes
- Hospitals & Clinics
- Others
Expert Views:
The UK Cdmo pharmaceuticals market is forecast to grow robustly in the years to come owing to rising outsourcing in the pharmaceutical industry, increased manufacture of biologicals, and increased spending on advanced pharmaceutical therapeutics. Increasing precision medicines, cell/gene therapy manufacturing, and pharmaceutical innovations through artificial intelligence will keep driving the demand for CDMO solutions.
Author: Sanket and Pranali By Spherical Insights and Consulting